证据
- How does low‐molecular‐weight heparin (LMWH) compare with unfractionated heparin (UFH) for adults with an acute medical illness and reduced mobility?
- How do low‐molecular‐weight heparin (LMWH), vitamin K agonists (VKAs), and direct oral anticoagulants (DOACs) compare for treatment of venous thromboembolism (VTE) in people with cancer?
- How do oral direct thrombin inhibitors and oral factor Xa inhibitors compare with standard anticoagulation for the treatment of pulmonary embolism?
使用此内容应接受我们的免责声明。
